ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early‐stage, nonbulky Hodgkin lymphoma

Abstract

Because of a low risk of disease recurrence, posttreatment radiologic surveillance appears to be unnecessary in patients with early-stage, nonbulky (CD20 negative) cHL who achieve a PET-detected CR with the ABVD combination alone. This will reduce cumulative radiation exposure and health care costs in a predominantly young patient population.